Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Higgins

Showing results (11-20 of 58) with videos related to

Pageof 6
Sort By:
Rural and Remote Health|September 14, 2015
An assessment of current antenatal care practices and identification of modifiable risk factors for prematurity and low birth weight infants in pregnancy in Solomon IslandsJames Cafaro, Elloise Randle, Penelope Wyche, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|December 17, 2008
Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: a dose-ranging studyFrank Kanniess, Louis-Philippe Boulet, Wladyslaw Pierzchala, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 1, 2019
Ivacaftor in cystic fibrosis with residual function: Lung function results from an N-of-1 studyJerry A Nick, Connie St Clair, Marion C Jones, et al.
Respiratory Care|August 29, 2013
Tobramycin inhalation powder in cystic fibrosis patients: response by age groupDavid E Geller, Samya Z Nasr, Simon Piggott, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 7, 2008
Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthmaDavid S Pearlman, Leon Greos, Craig LaForce, et al.
Respiratory Research|October 6, 2010
Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropiumClaus Vogelmeier, David Ramos-Barbon, Damon Jack, et al.
Arthroplasty Today|February 17, 2025
Outcomes of Primary Total Hip Arthroplasty Using Custom Femoral Stems in Patients With Secondary Hip Osteoarthritis: A Systematic ReviewKevin Ilo, Prith Hallikeri, Habillan Naathan, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 1, 2014
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutationKris De Boeck, Anne Munck, Seth Walker, et al.
BMC Pulmonary Medicine|March 10, 2010
Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week studyGregory Feldman, Thomas Siler, Niyati Prasad, et al.
Pulmonary Pharmacology & Therapeutics|January 19, 2010
Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless designPeter J Barnes, Stuart J Pocock, Helgo Magnussen, et al.
Pageof 6

Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
Rural and Remote Health|September 14, 2015
An assessment of current antenatal care practices and identification of modifiable risk factors for prematurity and low birth weight infants in pregnancy in Solomon IslandsJames Cafaro, Elloise Randle, Penelope Wyche, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|December 17, 2008
Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: a dose-ranging studyFrank Kanniess, Louis-Philippe Boulet, Wladyslaw Pierzchala, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 1, 2019
Ivacaftor in cystic fibrosis with residual function: Lung function results from an N-of-1 studyJerry A Nick, Connie St Clair, Marion C Jones, et al.
Respiratory Care|August 29, 2013
Tobramycin inhalation powder in cystic fibrosis patients: response by age groupDavid E Geller, Samya Z Nasr, Simon Piggott, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 7, 2008
Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthmaDavid S Pearlman, Leon Greos, Craig LaForce, et al.
Respiratory Research|October 6, 2010
Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropiumClaus Vogelmeier, David Ramos-Barbon, Damon Jack, et al.
Arthroplasty Today|February 17, 2025
Outcomes of Primary Total Hip Arthroplasty Using Custom Femoral Stems in Patients With Secondary Hip Osteoarthritis: A Systematic ReviewKevin Ilo, Prith Hallikeri, Habillan Naathan, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 1, 2014
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutationKris De Boeck, Anne Munck, Seth Walker, et al.
BMC Pulmonary Medicine|March 10, 2010
Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week studyGregory Feldman, Thomas Siler, Niyati Prasad, et al.
Pulmonary Pharmacology & Therapeutics|January 19, 2010
Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless designPeter J Barnes, Stuart J Pocock, Helgo Magnussen, et al.
Pageof 6